The Expression Of ERCC-1,P53,Bcl-2,MT And The Sensitivity Of Cisplatin-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer

Objective : The aim of this study is to determine the predictive value of excision repair cross complement-1( ERCC-1),P53,Bcl-2 and metallothionein(MT)expression and the sensitivity of cisplatin- based chemotherapy in advance non-small cell lung cancer(NSCLC). Methods: From February 2000 to June 2004, 51 specimens paraffin- embedded tissue of pathologically confirmed advanced NSCLC were included. All patients receive cisplatin contained regimen chemotherapy. The expression of ERCC-1,p53,Bcl-2 and MT in tumor samples were examined by immunohistochemical supervisiontm method . The response rates and survival data were analyzed according to the over-expression or not of these four parameters. Results: In these 51 patients , over expression rate of ERCC-1,P53,Bcl-2 and MT were 64.7%(33/51), 49.1%(26/51), 39.2%(20/51) and 43.1%(22/51).The response rate of cisplatin-based chemotherapy in negative group/ over expression group of ERCC-1,P53,Bcl-2 and MT were72.2%/42.4%,50%/55.6%, 47.6%/56.7%, 56.7%/47.6%,but only ERCC-1 has statistics difference (p=0.042). The average survivaltime in negative group/ over-expression group were 12.5/9.3 months for ERCC-1, 10.0/10.8 months for P53, 10.4/10.4 months for MT, 9.7/10.9 months for Bcl- 2.But only ERCC-1 has statistics difference (p=0.018).The 1 year survivaltime in negative group/over-expression group were 72.2%/ 30.3% for ERCC-1, 33.3%/55.6% for P53, 42.9%/50% for MT, 33.3%/53.3% for Bcl-2,but only ERCC-1 has statistics diference (P=0.004). Conclusion : ERCC-1 can be used as a molecular marker of cisplatin sensitivity and prognosis in advanced NSCLC patients. Whether P53,Bcl-2 or MT can be used as moledular markers...